Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | ZAP70 | P43403 | 10/20 | 0.32 |
| ▸ | SRC | P12931 | 7/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23578356 | 0.92 | MEN1 (0.33) | MEN1KMT2ALMNAZAP70SRC | |
| SCHEMBL25801748 | 0.91 | MAPT (0.41) | MEN1KMT2ALMNAZAP70SRC | |
| SCHEMBL25801774 | 0.91 | KMT2A (0.36) | MEN1KMT2ALMNAZAP70SRC | |
| SCHEMBL25801972 | 0.91 | MEN1 (0.35) | MEN1KMT2ALMNAZAP70SRC | |
| SCHEMBL25801790 | 0.89 | MEN1 (0.34) | MEN1KMT2ALMNAZAP70SRC | |
| SCHEMBL25801885 | 0.89 | MEN1 (0.42) | MEN1KMT2ALMNAZAP70SRC | |
| SCHEMBL25801813 | 0.88 | SRC (0.33) | MEN1KMT2ALMNASRC | |
| SCHEMBL25801784 | 0.88 | MAPT (0.39) | MEN1KMT2ALMNAZAP70SRC | |
| SCHEMBL25801911 | 0.88 | MAPT (0.37) | MEN1KMT2ALMNAMAPTPSMB5 | |
| SCHEMBL25801996 | 0.87 | MEN1 (0.36) | MEN1KMT2ALMNAZAP70SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219907-A1 | CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES | SITRYX THERAPEUTICS LIMITED (GB) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219907-A1 | CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES | CPA2, RO60, C5AR1 | MEN1 4504/4885KMT2A 3125/4885LMNA 3388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.